WILMINGTON, Del., Jan. 12 -- More than 80 Risk Evaluation and Mitigation Strategy (REMS) plans have been approved by theFood & Drug Administration since their inception in March 2008. Now, pharmaceutical companies must formally assess and report on how well these plans have actually been working in reducing drug risks, a mandated step
This will be the topic of an open industry webinar at 12 noon EST on Wednesday, January 13 entitled "Cracking the Code on REMS Assessments: Opportunities for Improvement and Redesign," It is the second in a series of monthly "Wednesday FoREMS" webinars sponsored by ParagonRx, a subsidiary of inVentiv Health, Inc. and a leading consulting company specializing in pharmaceutical risk management and optimizing medication.
"In many of the discussions we have held with pharmaceutical companies about REMS design and implementation, the most frequent questions we encounter are related to REMS assessment, particularly how to measure the effectiveness of Medication Guides and related communications," says Jeffrey Fetterman, CEO of ParagonRx. "This webinar will help companies better understand how to conduct these REMS assessments."
More information about registering for the "Wednesday FoREMS" webinar series can be found at www.paragonrx.com/rems-hub/forems/. Webinars will be held the second Wednesday of each month at 12 noon EST.
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...View All